Key Points
- Major shareholder Squadron Capital sold 250,000 ATEC shares on Nov. 24 at $20.62 for $5,155,000, cutting its stake to 10,895,045 shares (a 2.24% ownership decline); it also sold 250,000 shares on Nov. 12 at $20.80, bringing recent total sales to 500,000 shares (~$10.355M).
- Alphatec recently beat estimates with Q earnings of $0.03 EPS (vs. -$0.06) and revenue of $196.5M (up 30.4% YoY), shares trade near a 52-week high (~$21.83) and analysts are broadly positive (nine Buys, average price target $22.00, "Moderate Buy").
Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) major shareholder Squadron Capital Llc sold 250,000 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $20.62, for a total value of $5,155,000.00. Following the sale, the insider owned 10,895,045 shares of the company's stock, valued at approximately $224,655,827.90. This represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Squadron Capital Llc also recently made the following trade(s):
- On Wednesday, November 12th, Squadron Capital Llc sold 250,000 shares of Alphatec stock. The shares were sold at an average price of $20.80, for a total value of $5,200,000.00.
Alphatec Stock Performance
Shares of ATEC stock opened at $21.83 on Wednesday. Alphatec Holdings, Inc. has a fifty-two week low of $8.69 and a fifty-two week high of $22.00. The stock's 50-day moving average is $16.72 and its two-hundred day moving average is $14.32. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77. The firm has a market cap of $3.24 billion, a P/E ratio of -19.32 and a beta of 1.17.
Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.09. The firm had revenue of $196.50 million for the quarter, compared to analyst estimates of $182.78 million. The firm's quarterly revenue was up 30.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.28) earnings per share. Alphatec has set its FY 2025 guidance at EPS. Analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts have commented on the stock. Needham & Company LLC boosted their target price on shares of Alphatec from $16.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, October 31st. Stifel Nicolaus initiated coverage on shares of Alphatec in a report on Tuesday, October 28th. They set a "buy" rating and a $20.00 price target on the stock. Wells Fargo & Company upped their price objective on shares of Alphatec from $14.00 to $16.00 and gave the stock an "overweight" rating in a report on Thursday, October 16th. Morgan Stanley increased their target price on shares of Alphatec from $16.00 to $21.00 and gave the stock an "equal weight" rating in a research report on Monday, November 10th. Finally, Wall Street Zen upgraded Alphatec from a "hold" rating to a "buy" rating in a report on Saturday, October 18th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $22.00.
Read Our Latest Report on ATEC
Institutional Trading of Alphatec
Several large investors have recently modified their holdings of ATEC. LPL Financial LLC lifted its position in Alphatec by 1.2% during the 1st quarter. LPL Financial LLC now owns 418,061 shares of the medical technology company's stock worth $4,211,000 after acquiring an additional 4,826 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Alphatec by 0.8% in the first quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company's stock worth $60,990,000 after purchasing an additional 45,792 shares during the period. Deutsche Bank AG lifted its position in shares of Alphatec by 11.8% during the 1st quarter. Deutsche Bank AG now owns 1,185,235 shares of the medical technology company's stock worth $12,018,000 after purchasing an additional 124,785 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Alphatec by 4.6% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 40,734 shares of the medical technology company's stock valued at $413,000 after purchasing an additional 1,792 shares during the period. Finally, Zions Bancorporation National Association UT bought a new stake in Alphatec during the 1st quarter valued at approximately $2,240,000. 66.35% of the stock is owned by institutional investors.
About Alphatec
(
Get Free Report)
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
